Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: A phase 2a, open-label, single-dose escalation study

Article Medicine, General & Internal

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial

Robert L. Gottlieb et al.

Summary: The study showed that treatment with bamlanivimab and etesevimab was significantly associated with a reduction in SARS-CoV-2 viral load at day 11 in nonhospitalized patients with mild to moderate COVID-19, compared to placebo. However, bamlanivimab monotherapy did not show a significant reduction in viral load. Ongoing clinical trials will focus on assessing the clinical benefits of antispike neutralizing antibodies in COVID-19 patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Anil Gupta et al.

Summary: In this study, among nonhospitalized patients with symptomatic Covid-19, sotrovimab treatment significantly reduced the risk of disease progression leading to hospitalization or death compared to placebo. Patients receiving sotrovimab also had a lower rate of serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Interplay between Emerging SARS-CoV-2 Variants and Pandemic Control

Kathleen M. Neuzil

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

M. Dougan et al.

Summary: In this phase 3 trial, the combination of bamlanivimab plus etesevimab was found to reduce the incidence of Covid-19-related hospitalization and death among high-risk ambulatory patients compared to placebo, and also accelerated the decline in SARS-CoV-2 viral load.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Estimating infectiousness throughout SARS-CoV-2 infection course

Terry C. Jones et al.

Summary: In a study of SARS-CoV-2 cases in Germany, it was found that younger subjects had lower viral loads but higher cell culture replication probabilities compared to older subjects. Additionally, 8% of subjects had viral loads above 10(9) copies per swab, with a third of them being presymptomatic, asymptomatic, or mildly symptomatic individuals with a mean age of 37.6 years. The B.1.1.7 lineage infections had a higher viral load and cell culture replication probability than non-B.1.1.7 subjects.

SCIENCE (2021)

添加到收藏夹

Review Gastroenterology & Hepatology